Cytokinetics, Incorporated

CYTK

$66.95

Name : Cytokinetics, Incorporated

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $8,185,636,352.00

EPSttm : -6.3

Cytokinetics, Incorporated

$66.95

0.77%

$0.51

Float Short %

11.52

Margin Of Safety %

Put/Call OI Ratio

0.21

EPS Next Q Diff

-0.01

EPS Last/This Y

-0.84

EPS This/Next Y

0.32

Price

66.97

Target Price

78.44

Analyst Recom

1.43

Performance Q

76.93

Relative Volume

1.04

Beta

0.59

Ticker: CYTK

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	CYTK	59.35	0.16	0.55	107148
2025-10-21	CYTK	57.78	0.17	2.00	107529
2025-10-22	CYTK	54.8	0.17	0.24	108279
2025-10-23	CYTK	57.49	0.18	0.16	109723
2025-10-24	CYTK	57.82	0.18	2.35	110756
2025-10-27	CYTK	60.18	0.18	0.60	110937
2025-10-28	CYTK	62.01	0.18	0.18	111151
2025-10-29	CYTK	61.93	0.18	0.15	111272
2025-10-30	CYTK	62.3	0.18	0.33	111477
2025-10-31	CYTK	63.63	0.18	0.07	111665
2025-11-03	CYTK	60.01	0.18	0.04	112475
2025-11-04	CYTK	59.65	0.18	0.26	113139
2025-11-05	CYTK	58.56	0.18	0.27	113050
2025-11-06	CYTK	60.29	0.18	0.41	113096
2025-11-07	CYTK	60.16	0.18	0.52	113384
2025-11-10	CYTK	62.22	0.19	0.05	114212
2025-11-11	CYTK	66.79	0.19	1.57	114236
2025-11-12	CYTK	66	0.21	0.40	116445
2025-11-13	CYTK	65.52	0.21	1.12	118243
2025-11-14	CYTK	66.39	0.22	1.62	119045
2025-11-17	CYTK	66.97	0.21	0.13	119103
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	CYTK	59.35	-15.4	-115.1	-5.62
2025-10-21	CYTK	57.75	-15.4	-88.8	-5.62
2025-10-22	CYTK	54.76	-15.2	-73.1	-5.62
2025-10-23	CYTK	57.51	-15.2	-136.6	-5.62
2025-10-24	CYTK	57.76	-15.2	-108.3	-5.62
2025-10-27	CYTK	60.18	-15.2	-130.6	-5.62
2025-10-28	CYTK	61.97	-15.2	-123.9	-5.62
2025-10-29	CYTK	61.95	-15.2	-105.3	-5.62
2025-10-30	CYTK	62.25	-15.2	-108.1	-5.62
2025-10-31	CYTK	63.59	-15.2	-118.8	-5.62
2025-11-03	CYTK	59.99	-15.2	-70.3	-5.62
2025-11-04	CYTK	59.56	-15.2	-100.7	-5.62
2025-11-05	CYTK	59.37	-15.2	-102.9	-5.62
2025-11-06	CYTK	60.31	-15.2	-117.2	-5.62
2025-11-07	CYTK	60.16	-15.2	56.6	-5.62
2025-11-10	CYTK	62.20	-9.3	15.8	-5.62
2025-11-11	CYTK	66.50	-9.3	-24.4	-5.87
2025-11-12	CYTK	66.04	-9.3	22.1	-5.87
2025-11-13	CYTK	65.50	-7.5	22.2	-5.92
2025-11-14	CYTK	66.40	-7.5	9.7	-5.92
2025-11-17	CYTK	66.97	-9.5	13.0	-6.10
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	CYTK	-5.21	2.30	12.06
2025-10-21	CYTK	-5.21	2.30	12.06
2025-10-22	CYTK	-4.55	2.30	12.06
2025-10-23	CYTK	-4.55	2.30	12.06
2025-10-24	CYTK	-4.55	2.30	12.06
2025-10-27	CYTK	-4.55	2.40	12.13
2025-10-28	CYTK	-4.70	2.40	12.13
2025-10-29	CYTK	-4.70	2.40	12.13
2025-10-30	CYTK	-4.70	2.40	12.13
2025-10-31	CYTK	-4.70	2.40	12.13
2025-11-03	CYTK	-4.70	2.18	12.13
2025-11-04	CYTK	-4.70	2.18	12.13
2025-11-05	CYTK	-4.78	2.18	12.13
2025-11-06	CYTK	-4.64	2.18	12.13
2025-11-07	CYTK	-4.57	2.18	12.13
2025-11-10	CYTK	-4.48	1.53	11.87
2025-11-11	CYTK	-4.48	1.53	11.87
2025-11-12	CYTK	-4.48	1.53	11.53
2025-11-13	CYTK	-4.65	1.53	11.53
2025-11-14	CYTK	-4.65	1.53	11.52
2025-11-17	CYTK	-4.49	7.71	11.52
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-1.54

Avg. EPS Est. Current Quarter

-1.38

Avg. EPS Est. Next Quarter

-1.55

Insider Transactions

-4.49

Institutional Transactions

7.71

Beta

0.59

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

39.3

Max Drawdown 5-Year %

-72.4

Target Price

78.44

P/E

Forward P/E

PEG

P/S

93.86

P/B

P/Free Cash Flow

EPS

-6.31

Average EPS Est. Cur. Y

-6.1

EPS Next Y. (Est.)

-5.78

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-862.21

Relative Volume

1.04

Return on Equity vs Sector %

117.3

Return on Equity vs Industry %

132.3

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.48

EBIT Estimation

Cytokinetics, Incorporated

Sector: Healthcare

Industry: Biotechnology

Employees: 498

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

stock quote shares CYTK – Cytokinetics, Incorporated Stock Price stock today

news today CYTK – Cytokinetics, Incorporated stock forecast ,stock prediction 2023 2024 2025

marketwatch CYTK – Cytokinetics, Incorporated yahoo finance google finance

stock history CYTK – Cytokinetics, Incorporated invest stock market

stock prices CYTK premarket after hours

ticker CYTK fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: CYTK

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y